35P Feasibility and activity of megestrol acetate in addition to EDP-M as first-line therapy in patients with metastatic/unresectable adrenocortical carcinoma

Abstract:

Background EDP-M (etoposide, doxorubicin, cisplatin+ mitotane) is the standard first-line therapy for advanced adrenocortical carcinoma (ACC). Preclinical data from our lab showed that Progestins, commonly used in cancer patients to manage cachexia, exert a cytotoxic effect on ACC both in vitro and in vivo and could potentially improve EDP-M tolerability and efficacy. Methods We present the feasibility and tolerability of adding oral megestrol acetate (320 mg daily) to EDP-M (EDP-MM) in 24 metastatic ACC patients (pts) with low performance status (PS) consecutively followed in our center. Secondary objectives were to evaluate the objective response rate (ORR), the Clinical Benefit Rate (CBR), progression-free survival (PFS) and overall survival (OS). A control group of 48 patients treated with EDP-M alone was added, they were matched based on the propensity score according to the GRAS score. Results ECOG …

Año de publicación:

2023

Keywords:

Fuente:

google